Senseonics develops and provides the Eversense Continuous Glucose Monitoring (CGM) System, which is a long-term implantable device designed for diabetes management.

Senseonics

Senseonics, Incorporated | 11,715 followers on LinkedIn. Creators of the first and only long-term implantable CGM | Senseonics, Inc. is a medical device startup company in Germantown, Maryland, USA (near Washington, DC) developing transformative glucose monitoring products that are intended to enable people with diabetes to confidently live their lives with ease.   Utilizing breakthrough fluorescence sensing technology, the Senseonics continuous glucose monitoring (&quot;CGM&quot;​) system is being designed to be the first fully implantable CGM that is highly accurate and stable throughout its long sensor life.  

The system consists of a very small sensor implanted under the skin, an external transmitter, and a mobile medical application, which allows for discreet, easy access to real-time glucose measurements without the need for a dedicated receiver.

Technical Executive - Engineering R&D - IoT and AI - Technology Development - Product Management - Program Management - Seeking VP, Director and Sr…

Brian Thomas

Board Member and Audit Committee Chair

Doug Prince

Leading digital innovation at the heart of science and technology

Everett Lee

Medical Device Regulatory Affairs Professional, R&D Scientist, Project and Personnel Manager

Mark Mortellaro, PhD, RAC-Devices, RCC-MDR

Senseonics, Incorporated

We are delighted to announce our new agreement with Ascensia Diabetes Care “We are extremely excited to be partnering with Ascensia, a leader in the global diabetes space. Ascensia is well known for their high-quality CONTOUR products used by more than 10 million patients world-wide to help manage their diabetes. We believe their global commercial infrastructure and commitment to the Eversense systems will drive market adoption while allowing Senseonics to focus on further development of our implanted technology.” – Tim Goodnow

Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

COM:SENSEONICS

Senseonics

Last Close

0.32

21/11 21:00

Market Cap

237.15M

Beta: -

Volume Today

4.47M

Avg: -

Filings Not Available